



## **Catabasis Pharmaceuticals To Present At 2021 Wedbush PacGrow Healthcare Conference**

**BOSTON, Mass., August 4, 2021** – [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10<sup>th</sup>, 2021 at 8:35am ET. The session entitled “HAE Therapeutic Development Landscape in Hereditary Angioedema (HAE)” will include an overview of the HAE treatment landscape, information about Catabasis’s lead program QLS-215, and a Q&A session.

A webcast of the presentation will be available at the following link: <https://wsw.com/webcast/wedbush39/panel11/2571740>, and will also be available in the investors section of the Company’s website, [www.catabasis.com](http://www.catabasis.com), and will be archived for 30 days following the presentation.

### **About Catabasis**

At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

### **Catabasis Contacts:**

#### **Investor relations:**

Andrea Matthews

[investors@catabasis.com](mailto:investors@catabasis.com)

#### **Media:**

Elizabeth Higgins

[media@catabasis.com](mailto:media@catabasis.com)